FutureNeuro, Ireland’s premier Research Centre for Translational Brain Science, has unveiled a groundbreaking collaboration with Ozlo, the innovative company behind the Ozlo Sleepbuds®, to investigate the impact of wearable in-ear sleep technology on sleep disturbances in people living with epilepsy. This novel partnership seeks to harness advanced sleep science and user-centric technology to address one of the most challenging comorbidities of epilepsy: disrupted sleep quality and its consequential burden on patient well-being.

Epilepsy’s global prevalence touches approximately 50 million individuals, with about 45,000 affected in Ireland alone. Although antiepileptic drugs can control seizures in a majority of patients, an alarming 30 to 40 percent remain resistant to pharmacological interventions, experiencing continued seizure activity. This patient subgroup often endures persistent sleep disturbances and fatigue, which significantly degrade quality of life independently from seizure frequency or severity. The intricate interplay between epileptic seizures and sleep architecture represents a critical yet under-explored clinical frontier demanding innovative therapeutic strategies.

Seizure occurrence frequently aligns with circadian rhythms, the endogenous 24-hour cycles regulating physiological processes including the sleep–wake transition. Notably, seizures often manifest nocturnally, disrupting sleep continuity. This bi-directional relationship accentuates a vicious cycle where poor quality sleep increases seizure susceptibility, while seizures themselves, alongside medication side effects and nocturnal symptoms, further destabilize sleep patterns. Despite mounting neurophysiological evidence underscoring sleep’s role in epilepsy pathophysiology, routine epilepsy management seldom includes comprehensive sleep and circadian rhythm assessments, indicating a pressing need for integrated diagnostic and therapeutic approaches.

The EPI-SLEEP study (Effect of Personalised In-ear Sleep Technology on Sleep Disturbances in Epilepsy) represents a multidimensional research initiative led by Dr Cristina Reschke in concert with Dr Rob Argent at the School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, and FutureNeuro investigators. This study pioneers a home-based, non-invasive intervention deploying Ozlo Sleepbuds®, designed specifically for comfortable, all-night wear to mitigate environmental disruptions through adaptive audio masking technology, potentially fostering more consistent, uninterrupted sleep architecture.

Recruitment for the study targets 60 adults diagnosed with focal epilepsy experiencing significant sleep disturbances, encompassing both individuals responsive and resistant to pharmacological treatment regimens. Participants will undergo extensive baseline and interventional monitoring using multimodal approaches including portable biosensors, actigraphy-based wearable sleep trackers, salivary hormone sampling to assess circadian biomarkers such as cortisol and melatonin, and validated patient-reported sleep and mood diaries to capture subjective experiences. The study design incorporates a four-week period of continuous Ozlo Sleepbuds® usage at home, enabling real-world assessment of technological effects on sleep consolidation and circadian rhythm stabilization.

Underpinning the study’s rigor, the integration of objective biological markers and subjective psychometric data allows an unprecedented, holistic analysis of sleep modulation in epilepsy. By comprehensively evaluating circadian hormone profiles in conjunction with electro-physiological sleep patterns and patient quality of life indices, this research stands to elucidate the mechanistic undercurrents by which personalized adaptive soundscapes influence neural excitability and sleep homeostasis, potentially attenuating seizure frequency and improving daytime functioning and mood.

Dr Cristina Reschke emphasized the importance of addressing sleep as an integral component of epilepsy care, stating that many patients suffer from pervasive fatigue and poor restorative rest beyond the impact of seizures alone. Such findings could redefine epilepsy management paradigms by introducing validated, non-pharmacological options that complement existing treatments without exacerbating medication load, a critical consideration given the side effect profiles of many anti-seizure drugs.

Ozlo’s founder, N.B. Patil, articulated the company’s commitment to deploying science-backed, user-friendly sleep technology to deepen restorative rest. The partnership with FutureNeuro symbolizes a significant milestone in translating audio engineering innovations into tangible clinical benefits, highlighting a convergence of neuroscience research and consumer health technology aimed at transforming sleep health in clinical populations.

This collaboration aligns with FutureNeuro’s strategic emphasis on digital health solutions within neurological disease frameworks, leveraging advances in chronobiology and wearable technology for improved patient-centric outcomes. The implications of EPI-SLEEP extend beyond epilepsy, potentially informing therapeutic avenues in other neurological disorders characterized by circadian misalignment, such as Parkinson’s disease and multiple sclerosis, enhancing holistic neurotherapeutic strategies worldwide.

By advancing the science at the nexus of neurophysiology, circadian biology, and wearable innovation, the EPI-SLEEP project exemplifies the translational potential of interdisciplinary research in creating scalable, evidence-based, non-pharmacological interventions. Such approaches hold promise not only for seizure reduction but for enhancing overall neurological health and quality of life, addressing an urgent unmet clinical need in epilepsy care and beyond.

As digital health platforms and personalized medicine continue to evolve rapidly, studies like EPI-SLEEP are crucial for validating the efficacy and safety of emerging technologies in real-world contexts, thereby facilitating their integration into clinical practice. FutureNeuro’s partnership with Ozlo underscores a visionary blueprint for collaborative innovation that bridges fundamental neuroscience research, medical technology development, and patient empowerment through accessible, impactful solutions.

In a landscape where neurological disorders increasingly demand multifaceted treatment approaches, this pioneering research collaboration conveys optimism about the role of sleep technology in reshaping therapeutic paradigms. By bringing engineered audio solutions directly into patients’ lives, the study may set a precedent for next-generation interventions that transcend conventional pharmacotherapies, heralding a new era of neurotherapeutic care rooted in personalized, integrative modalities.

Subject of Research:
People living with epilepsy and sleep disturbances

Article Title:
Harnessing Wearable Sleep Technology to Combat Sleep Disruption in Epilepsy: The EPI-SLEEP Study

News Publication Date:
Tuesday, 9 June 2026

Web References:
https://futureneurocentre.ie/
https://ozlosleep.com/
http://www.ozlosleep.com/

Image Credits:
Credit: Ozlo

Keywords

Epilepsy, Neurological disorders, Sleep disturbances, Circadian rhythms, Sleep technology, Wearable devices, Non-pharmacological interventions, Neuroscience, Digital health, Personalized medicine, Neurophysiology, Sleepbuds

Tags: epilepsy and circadian rhythm disruptionsFutureNeuro epilepsy research centerimpact of sleep quality on seizure managementimproving quality of life in epilepsyinnovative epilepsy sleep therapiesmanaging drug-resistant epilepsy symptomsnon-pharmacological epilepsy treatmentsOzlo Sleepbuds sleep studysleep architecture and seizure occurrencesleep disturbances in epilepsy patientssleep-wake cycle and seizure correlationwearable in-ear sleep technology for epilepsy